FOLFOX4方案与XELOX方案治疗转移性结直肠癌的疗效与不良反应分析  

Efficacy and Adverse Effects of FOLFOX4 Regimen and XELOX Regimen in the Treatment of Metastatic Colorectal Cancer

作　　者：黄芳[1] 刘超英[1] 

机构地区：[1]江苏省无锡市人民医院,214023

出　　处：《实用癌症杂志》2016年第10期1675-1677,共3页The Practical Journal of Cancer

摘　　要：目的对比分析FOLFOX4和XELOX方案治疗的转移性结直肠癌的疗效和不良反应。方法选择转移性结直肠癌患者72例,按照姑息化疗方案的不同分为XELOX组38例和FOLFOX4组34例。XELOX组患者口服卡培他滨1000 mg/m2,早晚各服1次,连续服用14 d,奥沙利铂130 mg/m2静脉点滴,第1 d,21 d为一个治疗周期。FOLFOX4组患者奥沙利铂85 mg/m2静脉滴注2 h,第1 d,亚叶酸钙200 mg/m2静脉滴注2h,第1~2 d,5-氟尿嘧啶400 mg/m2快速静脉滴注后再用600 mg/m2静脉滴注22 h,第1~2 d,14 d为一个治疗周期。结果 XELOX组患者5年无病生存率为55.3%,FOLFOX4组患者5年无病生存率为45.2%,差异无统计学意义(χ2=1.531,P=0.216)。XELOX组患者有效率为52.6%,FOLFOX4组患者有效率为47.1%,两组有效率比较无显著差异(P>0.05)。XELOX组患者白细胞减少发生率为47.3%,血小板减少发生率为15.8%,显著低于FOLFOX4组(64.7%和32.4%),差异有统计学意义(P<0.05);XELOX组患者手足综合征的发生率为39.5%,显著高于FOLFOX组(8.8%),差异具有统计学意义(P<0.05)。结论XELOX方案治疗转移性结直肠癌的疗效与FOLFOX4相当,但是安全性较高。Objective To analyze the efficacy and adverse effects of FOLFOX4 and XELOX regimen in the treatment of metastatic colon cancer.Methods 72 patients with metastatic colorectal cancer were divided into XELOX group（38 cases） and FOLFOX4 group（34 cases） according to the different adjuvant chemotherapy regimens.XELOX group was treated with oral capecitabine 1 000 mg/m^2,2 times/d,continuous administration for 14 d,intravenous infusion of oxaliplatin 130 mg/m^2,first day,21 d for a treatment cycle.FOLFOX4 group was treated with intravenous infusion of oxaliplatin 85 mg/m2 for 2h,first day,intravenous infusion of leucovorin calcium 200 mg/m^2 for 2h,1-2 d,rapid intravenous injection of 5-FU 400 mg/m^2 and then intravenous infusion of 5-FU 600 mg for 22 h,1-2 d,14 d was a treatment cycle.Results 5-year disease-free survival rate in the XELOX group was 55.3%,and of FOLFOX4 group was 45.2%,the difference was not statistically significant（χ~2=1.531,P=0.216）.The effective rate of XELOX group was 52.6%,and of FOLFOX4 group was 47.1%,there was no significant difference in the effective rate between the 2 groups（P〉0.05）.In XELOX group,the incidence of leucopenia was 47.3%,the incidence of thrombocytopenia was 15.8%,which were significantly lower than those of FOLFOX4 group,64.7% and 32.4%,the difference was statistically significant（P〈0.05）.The incidence of hand foot syndrome in the XELOX group was 39.5%,which was significantly higher than that of FOLFOX group（8.8%）,the difference was statistically significant（P〈0.05）.Conclusion The efficacy of XELOX regimen in the treatment of metastatic colorectal cancer is similar to that of FOLFOX4,but the safety is higher.

关 键 词：卡培他滨 奥沙利铂 5-氟尿嘧啶 亚叶酸钙 转移性结直肠癌 

分 类 号：R735.37[医药卫生—肿瘤]